Literature DB >> 26395059

Neddylation in glioblastomas.

Sheila Mansouri1, Gelareh Zadeh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26395059      PMCID： PMC4578592          DOI： 10.1093/neuonc/nov165

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.

Authors:  Wei Hua; Chunjie Li; Zixiao Yang; Lihui Li; Yanan Jiang; Guangyang Yu; Wei Zhu; Zhengyan Liu; Shengzhong Duan; Yiwei Chu; Meng Yang; Yanmei Zhang; Ying Mao; Lijun Jia
Journal:  Neuro Oncol       Date:  2015-04-22       Impact factor: 12.300

Review 2.  Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.

Authors:  Meng Wang; Bruno C Medeiros; Harry P Erba; Daniel J DeAngelo; Francis J Giles; Ronan T Swords
Journal:  Expert Opin Ther Targets       Date:  2011-01-10       Impact factor: 6.902

3.  The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.

Authors:  Teresa A Soucy; Lawrence R Dick; Peter G Smith; Michael A Milhollen; James E Brownell
Journal:  Genes Cancer       Date:  2010-07

Review 4.  SCF E3 ubiquitin ligases as anticancer targets.

Authors:  L Jia; Y Sun
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

5.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 6.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206
  6 in total
  2 in total

1.  Systemic inhibition of neddylation by 3-day MLN4924 treatment regime does not impair autophagic flux in mouse hearts and brains.

Authors:  Casey A Reihe; Nickolas Pekas; Penglong Wu; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2017-12-20

2.  Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment.

Authors:  Natalia Filippova; Xiuhua Yang; Zixiao An; Louis B Nabors; Larisa Pereboeva
Journal:  J Cancer Sci Ther       Date:  2018-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.